Israel Englander’s Iovance Biotherapeutics IOVA Stock Holding History

Israel Englander’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-165,000	Closed	-$450K	–	6027
2025 Q4	$450K	Buy	+165,000	New	+$382K	﹤0.01%	5019
2023 Q4	–	Sell	-103,700	Closed	-$472K	–	6292
2023 Q3	$472K	Buy	+103,700	New	+$677K	﹤0.01%	4701
2022 Q3	–	Sell	-303,100	Closed	-$3.35M	–	7263
2022 Q2	$3.35M	Buy	+303,100	New	+$3.97M	﹤0.01%	3198
2021 Q2	–	Sell	-10,000	Closed	-$317K	–	6773
2021 Q1	$317K	Buy	+10,000	New	+$415K	﹤0.01%	5173
2020 Q2	–	Sell	-10,000	Closed	-$299K	–	4370
2020 Q1	$299K	Buy	+10,000	New	+$265K	﹤0.01%	3178

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's IOVA Position: Q2 2026 in Review

Israel Englander reduced its Iovance Biotherapeutics (IOVA) stake by 9.4% in Q2 2026, selling an estimated $3.38M and leaving 8,525,919 shares worth $35.5M. The position accounts for 0.01% of the portfolio, ranked #1146.

Israel Englander first reported a position in IOVA in Q1 2015 and has held it in 39 quarters since. The position peaked at $39.5M in Q1 2022. 289 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Israel Englander held 8,525,919 shares of Iovance Biotherapeutics worth $35.5M as of Q2 2026.
Israel Englander sold 888,373 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.38M.
Iovance Biotherapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1146 holding.
Israel Englander first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 39 quarters since.
Israel Englander's Iovance Biotherapeutics position peaked at $39.5M in Q1 2022.
289 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.